Cancer Family
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm
CI-CAN-00000039Explore in graph →
Non-malignant864 active trials6 approved drugs159 evidence items
- NCIt
- C35562
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000039Explore in graph →
Clinical trials
3,131 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02133183 | Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma | terminated | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2024 | clinicaltrials |
| NCT04556929 | Enhanced Detection in Glioma Excision(EDGE) | terminated | N/A | 4 | University of OxfordOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT03705351 |
| Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM |
| terminated |
| Phase 1 |
| 7 |
| Providence Health & ServicesOTHER |
| 1 |
| Mar 4, 2024 |
| clinicaltrials |
| NCT02905643 | Discerning Pseudoprogression vs True Tumor Growth in GBMs | terminated | — | 1 | Ascension HealthINDUSTRY | 0 | Feb 22, 2024 | clinicaltrials |
| NCT04341311 | Phase I Study of Marizomib + Panobinostat for Children With DIPG(DIPG) | terminated | Phase 1 | 4 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT01345136 | Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma | terminated | Phase 2 | 4 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT05394558 | AsiDNA Children, Adolescents and Young Adults(AsiDNA) | terminated | Phase 1 / Phase 2 | 8 | Institut CurieOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT02168270 | Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma | terminated | Phase 1 | 4 | University of NebraskaOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT02530502 | Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma | terminated | Phase 1 | 4 | Northwestern UniversityOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04763031 | Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT | terminated | N/A | 1 | Parkridge Medical CenterOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT03939858 | Bioenergetic Profiling and Cognition in GBM Patients | terminated | — | 6 | Wake Forest University Health SciencesOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT02833701 | Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma | terminated | Phase 1 | 9 | University of NebraskaOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT02659800 | Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas | terminated | Phase 1 | 12 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT03593993 | A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas | terminated | — | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT03971734 | Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas | terminated | Phase 1 | 7 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05116878 | Enhancing Facial Nerve Function With Omega-3 After Resection of Vestibular Schwannoma(EFFORTS) | terminated | N/A | 15 | Mayo ClinicOTHER | 1 | Sep 8, 2023 | clinicaltrials |
| NCT04608812 | Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection | terminated | Phase 1 | 7 | OncoSynergy, Inc.INDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT04541225 | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors | terminated | Phase 1 | 74 | Nuvation Bio Inc.INDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT04650204 | Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy | terminated | Phase 4 | 4 | Mayo ClinicOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03332355 | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2 | terminated | Phase 1 | 18 | Vanquish Oncology, Inc.INDUSTRY | 1 | May 24, 2023 | clinicaltrials |
| NCT01721577 | Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas(AXL1717) | terminated | Phase 1 / Phase 2 | 10 | Rush University Medical CenterOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT03436433 | Seizure Prophylaxis in Patients With Glioma or Brain Metastasis | terminated | Phase 2 | 4 | Duke UniversityOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT03714334 | DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma | terminated | Phase 1 | 16 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT04730349 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer(PIVOT IO 020) | terminated | Phase 1 / Phase 2 | 15 | Bristol-Myers SquibbINDUSTRY | 6 | Mar 24, 2023 | clinicaltrials |
| NCT01700569 | Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma(FOLAGLI) | terminated | Phase 1 | 24 | Institut Cancerologie de l'OuestOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT02664363 | EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma(ExCeL) | terminated | Phase 1 | 3 | Daniel LandiOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT02654340 | Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)(TuScCom) | terminated | — | 20 | CENTOGENE GmbH RostockINDUSTRY | 8 | Feb 10, 2023 | clinicaltrials |
| NCT03430791 | Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma | terminated | Phase 2 | 5 | Baptist Health South FloridaOTHER | 1 | Feb 2, 2023 | clinicaltrials |
| NCT01986348 | Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas(KING) | terminated | Phase 2 | 76 | Karyopharm Therapeutics IncINDUSTRY | 3 | Jan 26, 2023 | clinicaltrials |
| NCT02769806 | Advanced Perfusion MRI of Treatment Response and Progression in Glioblastoma | terminated | — | 16 | University of Wisconsin, MadisonOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT01822275 | Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme(GCC 1224) | terminated | Phase 2 | 24 | University of Maryland, BaltimoreOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT02023905 | Everolimus With and Without Temozolomide in Adult Low Grade Glioma | terminated | Phase 2 | 27 | University of California, San FranciscoOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT04851834 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma | terminated | Phase 1 / Phase 2 | 12 | Xennials Therapeutics Australia Pty LtdINDUSTRY | 1 | Dec 20, 2022 | clinicaltrials |
| NCT03119064 | BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma(329) | terminated | Phase 1 / Phase 2 | 12 | Brown UniversityOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT04895553 | Incidence of Intracranial Hemorrhage in Glioma Patients With Venous Thromboembolism Converted From LMWH to Apixaban | terminated | — | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT04782609 | Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma(Glio) | terminated | Phase 1 | 7 | Samus Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2022 | clinicaltrials |
| NCT01954576 | NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme | terminated | N/A | 21 | University of FloridaOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT02885324 | Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children | terminated | Phase 2 | 4 | Indiana UniversityOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT03352427 | Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations | terminated | Phase 2 | 3 | University of Michigan Rogel Cancer CenterOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT02601209 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma | terminated | Phase 1 / Phase 2 | 151 | National Cancer Institute (NCI)NIH | 1 | Aug 23, 2022 | clinicaltrials |
| NCT03856099 | TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab | terminated | Phase 2 | 19 | PharmAbcineINDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT03022578 | Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT04489420 | Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM(CYNK001GBM01) | terminated | Phase 1 | 3 | Celularity IncorporatedINDUSTRY | 1 | Aug 10, 2022 | clinicaltrials |
| NCT01884740 | Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 | terminated | Phase 1 / Phase 2 | 13 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT03727841 | Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2022 | clinicaltrials |
| NCT01452854 | Ovarian Aging in Low Grade Glioma (LGG) Treated With Temozolomide(OVA-LGG) | terminated | — | 2 | University of California, San FranciscoOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT02663271 | TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma | terminated | Phase 2 | 10 | University of FloridaOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT00479765 | A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma | terminated | Phase 1 / Phase 2 | 4 | Boston Scientific CorporationINDUSTRY | 1 | Jun 22, 2022 | clinicaltrials |
| NCT02864368 | Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens(PERFORMANCE) | terminated | Phase 1 | 27 | Eric Thompson, M.D.OTHER | 1 | Jun 9, 2022 | clinicaltrials |
| NCT00669669 | O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas | terminated | Phase 1 / Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Apr 4, 2024source: clinicaltrials